Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 16/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 16/20 | 0.81 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | MMP13 | P45452 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MMP14 | P50281 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333246 | 1.00 | MEN1 (0.81) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL15995453 | 1.00 | MEN1 (0.81) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL8887899 | 0.89 | MEN1 (1.00) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL7019338 | 0.89 | MEN1 (1.00) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL10036060 | 0.89 | MEN1 (1.00) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL17069352 | 0.87 | KMT2A (0.62) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL2338592 | 0.86 | KMT2A (0.77) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL2338597 | 0.86 | KMT2A (0.77) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL9650247 | 0.86 | MEN1 (0.79) | MEN1KMT2APOLBSMN1; SMN2MAPT | |
| SCHEMBL9650252 | 0.86 | MEN1 (0.79) | MEN1KMT2APOLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808448-B2 | Pharmaceutical compounds and use of same in cancer and tauopathies | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170273963-A1 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-09-28 | — | — | US | disclosed |
| US-9642843-B2 | Pharmaceutical compounds and use of same in cancer and tauopathies | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160000770-A1 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| WO-2014134243-A1 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1465882-A4 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1465882-A2 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| WO-2003060078-A2 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | MEN1 4537/4885KMT2A 2838/4885POLB 4703/4885 |
| US-20170273963-A1 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES | MAPT, PSEN2, PSEN1 | MEN1 2013/4885KMT2A 2026/4885POLB 1851/4885 |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | MEN1 4537/4885KMT2A 2838/4885POLB 4703/4885 |
| US-20160000770-A1 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES | MAPT, PSEN2, PSEN1 | MEN1 1895/4885KMT2A 1990/4885POLB 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.